Gabriel J. Robbie
About
Gabriel J. Robbie is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Gabriel J. Robbie has authored 46 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Immunology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gabriel J. Robbie's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Respiratory viral infections research (8 papers) and Systemic Lupus Erythematosus Research (7 papers). Gabriel J. Robbie is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Respiratory viral infections research (8 papers) and Systemic Lupus Erythematosus Research (7 papers). Gabriel J. Robbie collaborates with scholars based in United States, France and Argentina. Gabriel J. Robbie's co-authors include Varun Goel, Wendy I. White, Genevieve A. Losonsky, Xiaoping Zhang, Valerie A. Clausen, Kathryn Jensen, Barbara White, Marianne T. Sweetser, William F. Dall’Acqua and M. Pamela Griffin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
Gabriel J. Robbie
45 papers receiving 2.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gabriel J. Robbie United States | 24 | 1.1k | 770 | 504 | 438 | 380 | 46 | 2.7k | ||
| Mark Heaney United States | 31 | 2.1k 2.0× | 695 0.9× | 265 0.5× | 359 0.8× | 962 2.5× | 91 | 4.5k | ||
| Morten Hanefeld Dziegiel Denmark | 34 | 1.3k 1.2× | 701 0.9× | 245 0.5× | 227 0.5× | 534 1.4× | 130 | 3.5k | ||
| Atsushi Komatsuda Japan | 30 | 1.3k 1.2× | 588 0.8× | 128 0.3× | 525 1.2× | 248 0.7× | 193 | 3.5k | ||
| Katie Streicher United States | 26 | 668 0.6× | 676 0.9× | 139 0.3× | 254 0.6× | 604 1.6× | 62 | 2.4k | ||
| Nattiya Hirankarn Thailand | 33 | 1.5k 1.4× | 1.4k 1.8× | 202 0.4× | 865 2.0× | 385 1.0× | 175 | 4.2k | ||
| Steven N. Emancipator United States | 34 | 646 0.6× | 957 1.2× | 310 0.6× | 347 0.8× | 141 0.4× | 95 | 3.0k | ||
| Yonghua Sheng Australia | 25 | 950 0.9× | 666 0.9× | 317 0.6× | 658 1.5× | 164 0.4× | 46 | 2.5k | ||
| Shuen‐Kuei Liao Taiwan | 28 | 788 0.7× | 752 1.0× | 509 1.0× | 167 0.4× | 408 1.1× | 117 | 2.3k | ||
| Sue Stephens United Kingdom | 24 | 577 0.5× | 1.3k 1.6× | 442 0.9× | 351 0.8× | 431 1.1× | 36 | 3.4k | ||
| M. Hart Netherlands | 30 | 518 0.5× | 1.3k 1.7× | 560 1.1× | 343 0.8× | 400 1.1× | 44 | 2.7k |
Countries citing papers authored by Gabriel J. Robbie
Since
Specialization
Citations
This map shows the geographic impact of Gabriel J. Robbie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel J. Robbie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel J. Robbie more than expected).
Fields of papers citing papers by Gabriel J. Robbie
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gabriel J. Robbie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel J. Robbie. The network helps show where Gabriel J. Robbie may publish in the future.
Co-authorship network of co-authors of Gabriel J. Robbie
This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel J. Robbie. A scholar is included among the top collaborators of Gabriel J. Robbie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel J. Robbie. Gabriel J. Robbie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Badri, Prajakta, Bahru Habtemariam, Valerie A. Clausen, et al.. (2023). Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation. Clinical Pharmacokinetics. 62(10). 1509–1522.
2.
Lee, Jong-Tae, et al.. (2023). Pharmacokinetic‐pharmacodynamic model of urinary δ‐aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. CPT Pharmacometrics & Systems Pharmacology. 12(6). 842–852.
3.
Gupta, Sneha, Valerie A. Clausen, Jing Li, et al.. (2021). Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs in R&D. 21(4). 455–465.
4.
Habtemariam, Bahru, Verena Karsten, Husain Attarwala, et al.. (2020). Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clinical Pharmacology & Therapeutics. 109(2). 372–382.
5.
Goel, Varun, Nathalie Gosselin, Claudia Jomphe, et al.. (2020). Population Pharmacokinetic–Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration. Nucleic Acid Therapeutics. 30(3). 143–152.
6.
Badri, Prajakta, Xuemin Jiang, Anna Borodovsky, et al.. (2020). Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clinical Pharmacokinetics. 60(3). 365–378.
7.
Zhang, Xiaoping, Varun Goel, Husain Attarwala, et al.. (2019). Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis. The Journal of Clinical Pharmacology. 60(1). 37–49.
8.
Ali, Omar, Xiang‐Qing Yu, Gabriel J. Robbie, et al.. (2018). Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clinical Microbiology and Infection. 25(5). 629.e1–629.e6.
9.
Greth, Warren, Gabriel J. Robbie, Philip Z. Brohawn, Micki Hultquist, & Bing Yao. (2016). Targeting the Interferon Pathway with Sifalimumab for the Treatment of Systemic Lupus Erythematosus. Immunotherapy. 9(1). 57–70.
10.
Petri, Michelle, Daniel J. Wallace, Alberto Spindler, et al.. (2013). Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study. Arthritis & Rheumatism. 65(4). 1011–1021.
11.
Notario, Gerard, et al.. (2013). Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis. Pulmonary Pharmacology & Therapeutics. 26(6). 666–671.
12.
Narwal, Rajesh, Lorin Roskos, & Gabriel J. Robbie. (2013). Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus. Clinical Pharmacokinetics. 52(11). 1017–1027.
13.
Annunziata, Christina M., Elise C. Kohn, Patricia LoRusso, et al.. (2012). Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investigational New Drugs. 31(1). 77–84.
14.
Robbie, Gabriel J., Liang Zhao, John Mondick, Genevieve A. Losonsky, & Lorin Roskos. (2012). Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children. Antimicrobial Agents and Chemotherapy. 56(9). 4927–4936.
15.
Parker, Joseph M., Chad K. Oh, Craig LaForce, et al.. (2011). Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulmonary Medicine. 11(1). 14–14.
16.
Mulgrew, Kathy, David J. Stewart, Wendy L. Trigona, et al.. (2008). Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models. Cancer Research. 68. 2131–2131.
17.
Robbie, Gabriel J., et al.. (1999). Poor and Unusually Prolonged Oral Absorption of Amphotericin B in Rats. Pharmaceutical Research. 16(3). 455–458.
18.
Chiou, Win L., et al.. (1998). Correlation of Plasma Clearance of 54 Extensively Metabolized Drugs Between Humans and Rats: Mean Allometric Coefficient of 0.66. Pharmaceutical Research. 15(9). 1474–1479.
19.
Chiou, Win L., Sang M. Chung, & Gabriel J. Robbie. (1997). Similarity or Discrepancy in Pharmacokinetic Parameter Estimation Between Bolus and Infusion Studies. Journal of Pharmacokinetics and Biopharmaceutics. 25(4). 471–476.
20.
Gulati, Anil, Avadhesh C. Sharma, Gabriel J. Robbie, & Pramod R. Saxena. (1995). Endothelin ETA receptor antagonist, BQ-123, blocks the vasoconstriction induced by sarafotoxin 6b in the heart but not in other vascular beds. General Pharmacology The Vascular System. 26(1). 183–193.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mark Heaney Breakdown of academic impact, for papers by Morten Hanefeld Dziegiel Breakdown of academic impact, for papers by Atsushi Komatsuda Breakdown of academic impact, for papers by Katie Streicher Breakdown of academic impact, for papers by Nattiya Hirankarn Breakdown of academic impact, for papers by Steven N. Emancipator Breakdown of academic impact, for papers by Yonghua Sheng Breakdown of academic impact, for papers by Shuen‐Kuei Liao Breakdown of academic impact, for papers by Sue Stephens Breakdown of academic impact, for papers by M. Hart